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Abstract
This is the ﬁrst in a new series of case reports that will present real scenarios from our community hospital. The cases
are chosen to highlight clinical dilemmas and offer review and perspective on what is currently known about the topic.
We present the case of a 55-year-old Caucasian male who presented to the emergency department of our community
hospital for worsening dyspnea. Evaluation in the Emergency department revealed a diagnosis of extensive pulmonary
emboli in the pulmonary vasculature. The patient was admitted to the ICU. A clinical decision was made to initiate
treatment with low-dose tissue plasminogen activator (tpa) followed by intravenous heparin infusion. Several hours
later the patient developed signiﬁcant epistaxis. A decision was made to stop the heparin infusion. Later that day, the
patient had abrupt clinical deterioration with subsequent cardiac arrest and did not recover. We discuss the classiﬁcation
and treatment of acute pulmonary embolism, the management of epistaxis in an anticoagulated patient, and the clinical
conundrum of balancing active bleeding in patient requiring anticoagulation.
Keywords: Pulmonary embolism, Low-dose tpa, Epistaxis, Anticoagulation, Risk of anticoagulation versus bleeding

T

his inaugural case highlights the challenges
physicians face when weighing the beneﬁts
and risks of treatment with therapeutic anticoagulation when unexpected bleeding occurs.

The clinical teams’ relevant questions:
1. How should signiﬁcant pulmonary embolisms
be classiﬁed and treated?
2. How should epistaxis be managed in a patient
requiring systemic anticoagulation?
3. When do risks outweighs beneﬁts when anticoagulating a patient with active bleeding? Do
clear guidelines exist?

1. Case summary
We report a case of a 55-year-old Caucasian male
who presented to the emergency department of our

community hospital for worsening dyspnea. His
shortness of breath started three days prior and was
associated with a pre-syncopal event, pleuritic-type
chest pain, and a cough productive of blood-tinged
sputum. His only pertinent past medical history was
atrial ﬁbrillation, for which he was taking propafenone 225 mg every 8 h; he was not on any systemic
anticoagulation. He had no allergies to medications,
no pertinent family history, and no personal history
of smoking, alcohol, or drug use.
He denied any systemic symptoms such as fever
and chills, recent travel, or sick contacts. Review of
systems was positive for decrease in activity,
decrease in appetite, and fatigue, but was otherwise
negative. In the emergency department, his vital
signs were signiﬁcant for a heart rate of 166 beats
per minute that was irregularly irregular, and a
SpO2 of 88%. He was afebrile and had blood pressure of 127/74. His respiratory rate was 33 The
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physical exam was also signiﬁcant for diminished
breath sounds in bilateral lower lung ﬁelds; the
remainder of exam was normal. ECG shown below.

Laboratory evaluations were only signiﬁcant for
the following: Cr 2.1, glucose 221, lactic acid 3.0,
troponin 0.96, pro-BNP 1.945, and a D dimer of
greater than 20. Due to hypoxia, a PCR COVID was
performed, which was negative. Initial diagnostic
workup included an EKG, which demonstrated
atrial ﬁbrillation with rapid ventricular response. A
chest x-ray did not reveal any acute cardiopulmonary process. CXR shown below.

Supplemental oxygen of four liters via nasal
cannula was initiated, a one-liter normal saline
ﬂuid bolus was given, and three doses of diltiazem

10 mg were administered intravenously. The patient was also treated with ceftriaxone and doxycycline for
possible
community
acquired
pneumonia.
A bedside point of care ultrasound (POCUS)
demonstrated a 1:1 ratio of the right ventricle to the
left ventricle, right ventricular basilar hypokinesis
and apical hyperkinesis, also known as a positive
McConnel sign. Given the high concern for PE, a CT

angiography of the chest was performed, which
revealed:
“There are extensive bilateral pulmonary emboli
present within the distal portion of the central
pulmonary arteries bilaterally, with a small
amount of thrombus also present in the region of
the bifurcation. There are emboli extending into
the ﬁrst and second order branches within the
upper and lower lobes bilaterally …”
See CT image below:

The patient was admitted to the ICU for close
observation and medical management of a pulmonary embolism. After discussion with the clinical
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team regarding the risks and beneﬁts of systemic
thrombolytics, the patient agreed to proceed with
the recommended low-dose tissue plasminogen
activator (TPA) 20 mg IV administered over 8 h.
After completion of the TPA, a heparin infusion was
initiated.
The patient's oxygen requirement decreased.
However, approximately 6 h after the initiation of
the heparin drip, the patient was noted to have severe epistaxis. At that time, the decision was made
to hold the heparin drip. Oxymetazoline nasal spray

was administered, and nasal packing was applied.
Despite these measures, the nasal bleeding
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persisted. STAT labs revealed a stable hemoglobin
level (12.2 g/dL).
Approximately 12 h after the heparin drip was
stopped, the patient became tachycardic (heart rate
125) with severe dyspnea, then became pulseless
and developed cardiopulmonary arrest. Unfortunately, the patient was pronounced dead after
resuscitative efforts were unsuccessful.

What is known about the classiﬁcation and
treatment of acute pulmonary embolism?
Bobby Mathew, MD
Venous thromboembolic disease (VTE) is among
the leading causes of morbidity in the world and
results in the hospitalization of >250,000 Americans
annually (1). VTE can manifest as deep venous
thromboses (DVT) or as an acute pulmonary embolism (PE). Treatment for DVT is typically limited
to full dose anticoagulation with subcutaneous lowmolecular-weight heparin (LMWH), intravenous
unfractionated heparin infusion (UFH), a vitamin K
antagonist with appropriate parenteral bridging, or
any of several direct-acting oral anticoagulants
(DOACs) (2). The management of acute PE, however, is dependent on the severity of disease and is a
topic of much debate. There is a general consensus
regarding patients with acute PE who have very low
risk disease as well as those with very high-risk
disease. It is in those patients who reside in the intermediate range of severity that there is far less
certainty regarding the optimal treatment strategy.
Here we will discuss the classiﬁcation scheme for
pulmonary embolism as well as the accepted treatment modalities and guideline recommended
approach to early management.
Historically, PE has been classiﬁed into three
broad categories: massive PE, sub-massive PE, and
low-risk PE. Massive PE has been deﬁned by the
American Heart Association as acute PE with sustained hypotension (SBP <90 mmHg for over
15 min or requiring inotropic support) that is
thought to not be from a cause other than PE, cardiac arrest, or severe bradycardia (pulse <40). Submassive PE is an acute PE that is absent overt signs
of shock, but with clinical evidence of RV dysfunction in the form of RV dilation or dysfunction on
echocardiography, RV dilation on CT, an elevated
B-type natriuretic peptide, an elevated troponin, or
EKG changes suggestive of RV strain. Low-risk PE
is deﬁned as disease that lacks any of these features
(1). The American College of Chest Physicians
(ACCP) has similar deﬁnitions when deﬁning PE
risk severity. The European Society of Cardiology
(ESC) refers to massive PE as high-risk PE though it

is also deﬁned by the presence of hemodynamic
instability. Sub-massive PE is identiﬁed as intermediate risk PE by the ESC (3). Short-term mortality is markedly different among these groups,
ranging from ~1% at 30 days in the low-risk group
to >50% in the group presenting with massive/
high-risk PE (4).
The consensus recommendation for low-risk PE is
full-dose anticoagulation with any of the pharmacologic agents previously described for the treatment of acute DVT. Absent progression of disease
severity, the risks of more aggressive treatment
appear to outweigh the potential beneﬁts. For highrisk PE, there is again, little controversy regarding
the optimal treatment algorithm. Absent contraindications for systemic thrombolytic therapy - initial
reperfusion with systemic thrombolysis is the
guideline recommendation.1e3 Marti et al. demonstrated in a meta-analysis of systemic thrombolysis
that there was a reduction in all-cause mortality in
the thrombolysis group when studies that included
high-risk PE were used in the analysis.5 The rate of
fatal bleeding and intracranial hemorrhage was
signiﬁcantly higher in the thrombolysis group,
however (OR 3.18). Both the ACCP and ESC make a
recommendation for short duration infusions (2 h)
of thrombolytics in high-risk PE over longer infusions (24 h). Similarly, both state that full dose
anticoagulation with UFH can be maintained while
infusing TPA, though this practice is far less common in the United States.2,3
Percutaneous catheter directed treatments exist
for the management of PE as well. These procedures
typically involve the insertion of a catheter into the
pulmonary arteries, which can then be used for
direct mechanical fragmentation, thrombus aspiration, ultrasound-based fragmentation, or directed
low dose thrombolysis. In an RCT comparing catheter directed thrombolysis vs UFH alone, Kucher
et al. demonstrated a signiﬁcant decrease in RV/LV
diameter ratio at 24h in the catheter directed
thrombolysis group without an increase in bleeding
complications. Given the overall paucity of high
quality data for catheter directed therapy, both the
ACCP and ESC only recommend the use of a
catheter directed treatment strategy in patients with
high-risk PE and a contraindication to systemic
thrombolysis, have failed thrombolysis, or are likely
to die before systemic thrombolysis can have an
effect. More specialized therapies including surgical
embolectomy and ECMO are also available at tertiary care facilities for selected patients though the
evidence regarding these strategies remains
limited.3

Intermediate-risk or sub-massive PE presents a
more complicated question regarding the optimal
early treatment strategy. These patients demonstrate
clinical evidence of RV dysfunction or myocardial
necrosis without sustained hypotension or obstructive shock. Mortality estimates for intermediate risk
PE range from 1.8% to 15%.4,6 Several studies have
attempted to answer the question as to whether systemic thrombolytics have a role in the management
of intermediate-risk PE. The most notable among
them is the PEITHO Trial by Meyer et al. The PEITHO investigators conducted an RCT comparing
systemic TPA with UFH vs UFH alone. The trial
demonstrated a statistically signiﬁcant difference in
the composite endpoint of death or hemodynamic
decompensation (2.6% in the thrombolytics group vs
5.6% in the UFH alone group). Seven-day mortality,
however, was not signiﬁcantly different (1.2% vs
1.8%) but there was a statistically signiﬁcant difference in the incidence of hemorrhagic stroke (2.0% in
the thrombolysis group vs 0.2% in the UFH alone
group).
In light of the signiﬁcant heterogeneity among
patients with intermediate-risk PE and in the face of
an unclear beneﬁt to early systemic thrombolysis,
both the ACCP and ESC recommend against the
routine use of TPA in all patients presenting without
high-risk PE.2,3 Both groups make recommendation
to pursue a reperfusion strategy in patients who
demonstrate evidence of clinical worsening while
on anticoagulation so long as there is no contraindication to systemic thrombolytic therapy. There is a
growing body of literature that is attempting to
identify those patients with intermediate-risk PE
that are likely to face a higher risk of mortality and,
therefore, may warrant consideration for early
reperfusion. The quality of evidence for making this
assessment based on any one clinical parameter is
presently not robust, however.

What is known about managing acute
epistaxis in a patient on systemic anticoagulation?
Douglas Reh, MD
Epistaxis is one of the most common otorhinolaryngologic emergencies. It is estimated that
60% of the general population will suffer from at
least one episode and 6% will seek medical intervention for epistaxis at some point in their lives.7
The severity of this condition runs the spectrum
from isolated, minor episodes handled in the
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emergency room or clinic setting to life-threatening
instances of near exsanguination requiring deﬁnitive management. 90% of nosebleeds originate from
the anterior plexus of vessels, Kiesselbach's plexus,
located on the caudal septal mucosa. 45% of patients
hospitalized for epistaxis had some type of systemic
illness.8 In a study of these patients, 33% had hypertension, 15% were on anti-coagulation and 0.9%
had an underlying coagulopathy.
The traditional approach to managing epistaxis is
to apply pressure with direct compression to the
caudal septum and the vessels on Kiesselbach's
plexus where most nosebleeds occur. Direct visualization and cauterization of the bleeding area is
ideal. However, in some cases that cannot be achieved. Nasal packing can be helpful when cauterization is not feasible as packs can apply diffuse
pressure to the source of bleeding.
Bleeding in typical epistaxis usually occurs from a
discrete mucosal vessel. However, epistaxis in anticoagulated patients can be caused by diffuse
mucosal bleeding from multiple sources. Controlling epistaxis in an anti-coagulated patient requires
a different approach. Topical nasal decongestants
such as oxymetazoline work by causing vasoconstriction. A retrospective study of 60 patients treated
in the ER for epistaxis showed that 65% of those
patients were successfully treated with oxymetazoline.9 These provide an excellent means of stopping
nosebleeds. The placement of a nasal pack inherently causes mucosal trauma. Placing a nasal pack in
an anti-coagulated patient, whose mucosal bleeding
may be diffuse, may cause trauma that can increase
bleeding. The use of dissolvable packing with procoagulant properties can control bleeding in atraumatic fashion and is preferred in these patients.
Dissolvable packing or injectable pro-coagulant
foams can be used to control epistaxis. These
include products that use oxidized regenerated
cellulose (Surgicel®, Johnson & Johnson, Inc.),
collagen granules coated in thrombin (Floseal®,
Baxter), and injectable carboxy methylcellulose
(Sinu-foam®, Smith and Nephew).
Managing epistaxis in inpatients can be challenging, especially in patients with signiﬁcant comorbidities such as poorly controlled hypertension
or those who are anti-coagulated. The use of topical
vasoconstrictors and dissolvable pro-coagulant materials is a good ﬁrst option for controlling bleeding
in these patients. The treating physician should
have a low threshold for consulting an Otolaryngologist if these measures fail to control bleeding.
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What is known about interrupting
recommended anticoagulation in a patient
with bleeding?
Jerrica Mueller, MD

This case presentation exempliﬁes the challenge
in making clinical judgments regarding the need for
systemic anticoagulation and the risk of related
bleeding.
Reasonable physicians may disagree on the
importance of maintaining anticoagulation and the
degree of risk in speciﬁc cases. The complexity in
clinical decision-making is related to each patient's
unique set of risk factors for thrombosis and
bleeding. Often patients are elderly and have significant co-morbidities such as hypertension.10
Risk calculators may serve as useful tools to focus the
risks of anticoagulation management. For example, in
atrial ﬁbrillation, the CHADsVASC and HASBLED
scores help to determine an individual's risk of stroke
and the subsequent risk of bleeding with anticoagulation. Each risk score is stratiﬁed into low,
moderate, and high risk, allowing clinician the ability
to compare risk of thromboembolism with risk of
bleeding through numerical scoring. However, there
is little high-quality evidence on how to use these tools
to guide our treatment in patient care.10
Many patient care scenarios, including our case,
are not addressed by existing tools. How should
one proceed when a patient requiring anticoagulation develops an acute bleed? The site of
bleeding is an important consideration. Two of the
most feared complications of systemic anticoagulation are gastrointestinal bleeding and
intracranial bleeding. Epistaxis, as in our case, is
generally less morbid.
Annual bleeding rates of patients on oral anticoagulant therapy range from 2% to 5% for major
bleeding, 0.5% to 1% for fatal bleeding, and 0.2% to
0.4% for intracranial bleeding.11 It is important to
note that not all bleeds carry the same risk for harm.
For example, intracranial hemorrhages (ICH) result
in morbidity or mortality in up to 76% of cases while

extracranial bleeding, including gastrointestinal
bleeds, hematuria and epistaxis, lead to death or
disability in only 3% of cases.12
If a patient survives a major anticoagulant-related
bleed, another dilemma surfaces: when is it safe to
restart anticoagulation? Universal expert consensus
standards are lacking. For one of the more lethal of
bleeding scenarios, an anticoagulation-related
intracranial hemorrhage, a three-step approach has
been proposed to assist decision-making surrounding resumption of anticoagulation therapy. The ﬁrst
step evaluates the individual risk of thromboembolism and hemorrhage. The second step selects the
optimal anticoagulant and appropriate timing to
reinitiate therapy. Finally, reducing the risk of
recurrent hemorrhage through improving modiﬁable risk factors.10
While the three-step approach presented by Li
and Lip was designed speciﬁcally to address anticoagulation in the context of an intracranial hemorrhage, there may be value in using a similar
approach in other types of bleeds. In our patient
with epistaxis, this type of model could provide a
systematic approach to evaluating indications for
anticoagulation and minimizing future bleed risk.
With a goal of improving patient outcomes, the
safest approach utilizes a multidisciplinary team to
guide the complex decision-making. Depending on
whether anticoagulation is ceased or resumed, these
decisions often have a signiﬁcant impact on
morbidity and mortality.
Further study and analysis of multiple case scenarios and outcomes is suggested to help create and
develop expanded anticoagulation models and
guidelines in the future. One can imagine a Clot/
Bleed Predication Index App on future clinicians’
smartphones.
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